| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.955 | 0.002 | 0.955 | Phosphodiesterase V inhibitor | 0.955 0.002 DBMET03416 | ||
| 0.944 | 0.002 | 0.944 | Phosphodiesterase 5A inhibitor | 0.944 0.002 DBMET03416 | ||
| 0.753 | 0.001 | 0.753 | Phosphodiesterase 6C inhibitor | 0.753 0.001 DBMET03416 | ||
| 0.701 | 0.001 | 0.701 | Phosphodiesterase 6D inhibitor | 0.701 0.001 DBMET03416 | ||
| 0.696 | 0.001 | 0.696 | Phosphodiesterase 11A inhibitor | 0.696 0.001 DBMET03416 | ||
| 0.696 | 0.001 | 0.696 | Phosphodiesterase XI inhibitor | 0.696 0.001 DBMET03416 | ||
| 0.695 | 0.001 | 0.695 | Phosphodiesterase VI inhibitor | 0.695 0.001 DBMET03416 | ||
| 0.661 | 0.009 | 0.661 | 5 Hydroxytryptamine release stimulant | 0.661 0.009 DBMET03416 | ||
| 0.637 | 0.004 | 0.637 | Phosphodiesterase inhibitor | 0.637 0.004 DBMET03416 | ||
| 0.593 | 0.005 | 0.593 | Alpha adrenoreceptor antagonist | 0.593 0.005 DBMET03416 | ||
| 0.565 | 0.001 | 0.565 | Phosphodiesterase 6B inhibitor | 0.565 0.001 DBMET03416 | ||
| 0.548 | 0.001 | 0.548 | Phosphodiesterase 6G inhibitor | 0.548 0.001 DBMET03416 | ||
| 0.548 | 0.001 | 0.548 | Phosphodiesterase 6H inhibitor | 0.548 0.001 DBMET03416 | ||
| 0.495 | 0.011 | 0.495 | Psychostimulant | 0.495 0.011 DBMET03416 | ||
| 0.456 | 0.016 | 0.456 | Antimitotic | 0.456 0.016 DBMET03416 | ||
| 0.441 | 0.005 | 0.441 | Alpha 1 adrenoreceptor antagonist | 0.441 0.005 DBMET03416 | ||
| 0.339 | 0.002 | 0.339 | Phosphodiesterase 6A inhibitor | 0.339 0.002 DBMET03416 | ||
| 0.435 | 0.098 | 0.435 | Apoptosis agonist | 0.435 0.098 DBMET03416 | ||
| 0.303 | 0.047 | 0.303 | Vasodilator | 0.303 0.047 DBMET03416 | ||
| 0.259 | 0.004 | 0.259 | Kinesin antagonist | 0.259 0.004 DBMET03416 | ||
| 0.259 | 0.004 | 0.259 | Kinesin-like protein 1 inhibitor | 0.259 0.004 DBMET03416 | ||
| 0.262 | 0.011 | 0.262 | Alpha 1a adrenoreceptor antagonist | 0.262 0.011 DBMET03416 | ||
| 0.31 | 0.067 | 0.31 | Interleukin 2 agonist | 0.31 0.067 DBMET03416 | ||
| 0.313 | 0.073 | 0.313 | Caspase 3 stimulant | 0.313 0.073 DBMET03416 | ||
| 0.249 | 0.017 | 0.249 | Topoisomerase I inhibitor | 0.249 0.017 DBMET03416 | ||
| 0.242 | 0.011 | 0.242 | Alpha 1b adrenoreceptor antagonist | 0.242 0.011 DBMET03416 | ||
| 0.244 | 0.019 | 0.244 | CDC-like kinase 1 inhibitor | 0.244 0.019 DBMET03416 | ||
| 0.244 | 0.026 | 0.244 | 5 Hydroxytryptamine antagonist | 0.244 0.026 DBMET03416 | ||
| 0.237 | 0.026 | 0.237 | Topoisomerase II inhibitor | 0.237 0.026 DBMET03416 | ||
| 0.217 | 0.009 | 0.217 | Antineoplastic alkaloid | 0.217 0.009 DBMET03416 | ||
| 0.264 | 0.057 | 0.264 | Cyclic AMP phosphodiesterase inhibitor | 0.264 0.057 DBMET03416 | ||
| 0.211 | 0.006 | 0.211 | CDC-like kinase 3 inhibitor | 0.211 0.006 DBMET03416 | ||
| 0.207 | 0.022 | 0.207 | Alpha 2b adrenoreceptor antagonist | 0.207 0.022 DBMET03416 | ||
| 0.195 | 0.025 | 0.195 | Antiadrenergic | 0.195 0.025 DBMET03416 | ||
| 0.224 | 0.055 | 0.224 | Sigma receptor agonist | 0.224 0.055 DBMET03416 | ||
| 0.244 | 0.075 | 0.244 | Tyrosine 3 hydroxylase inhibitor | 0.244 0.075 DBMET03416 | ||
| 0.187 | 0.026 | 0.187 | Adrenaline antagonist | 0.187 0.026 DBMET03416 | ||
| 0.177 | 0.019 | 0.177 | 5 Hydroxytryptamine 1 antagonist | 0.177 0.019 DBMET03416 | ||
| 0.167 | 0.011 | 0.167 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.167 0.011 DBMET03416 | ||
| 0.173 | 0.018 | 0.173 | Breast cancer-resistant protein inhibitor | 0.173 0.018 DBMET03416 | ||
| 0.172 | 0.018 | 0.172 | 5 Hydroxytryptamine 1A antagonist | 0.172 0.018 DBMET03416 | ||
| 0.176 | 0.023 | 0.176 | Alpha 2c adrenoreceptor antagonist | 0.176 0.023 DBMET03416 | ||
| 0.183 | 0.031 | 0.183 | DNA intercalator | 0.183 0.031 DBMET03416 | ||
| 0.161 | 0.029 | 0.161 | Polo-like kinase-4 inhibitor | 0.161 0.029 DBMET03416 | ||
| 0.197 | 0.067 | 0.197 | 5 Hydroxytryptamine 3E antagonist | 0.197 0.067 DBMET03416 | ||
| 0.151 | 0.028 | 0.151 | 5 Hydroxytryptamine 2A antagonist | 0.151 0.028 DBMET03416 | ||
| 0.225 | 0.102 | 0.225 | 5 Hydroxytryptamine 1E antagonist | 0.225 0.102 DBMET03416 | ||
| 0.239 | 0.117 | 0.239 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.239 0.117 DBMET03416 | ||
| 0.164 | 0.042 | 0.164 | MAP3K9 inhibitor | 0.164 0.042 DBMET03416 | ||
| 0.305 | 0.188 | 0.305 | Caspase 9 stimulant | 0.305 0.188 DBMET03416 | ||
| 0.247 | 0.13 | 0.247 | Vasodilator, peripheral | 0.247 0.13 DBMET03416 | ||
| 0.158 | 0.046 | 0.158 | Glutamate receptor antagonist | 0.158 0.046 DBMET03416 | ||
| 0.133 | 0.022 | 0.133 | Phosphodiesterase I inhibitor | 0.133 0.022 DBMET03416 | ||
| 0.213 | 0.104 | 0.213 | DNA synthesis inhibitor | 0.213 0.104 DBMET03416 | ||
| 0.15 | 0.044 | 0.15 | 5 Hydroxytryptamine 2 antagonist | 0.15 0.044 DBMET03416 | ||
| 0.182 | 0.078 | 0.182 | P-glycoprotein inhibitor | 0.182 0.078 DBMET03416 | ||
| 0.108 | 0.008 | 0.108 | Phosphodiesterase 1A inhibitor | 0.108 0.008 DBMET03416 | ||
| 0.13 | 0.033 | 0.13 | Alpha 2 adrenoreceptor antagonist | 0.13 0.033 DBMET03416 | ||
| 0.2 | 0.115 | 0.2 | DNA damaging | 0.2 0.115 DBMET03416 | ||
| 0.126 | 0.046 | 0.126 | Sphingosine 1-phosphate receptor 2 agonist | 0.126 0.046 DBMET03416 | ||
| 0.179 | 0.104 | 0.179 | HERG channel blocker | 0.179 0.104 DBMET03416 | ||
| 0.092 | 0.019 | 0.092 | Alpha 1 adrenoreceptor agonist | 0.092 0.019 DBMET03416 | ||
| 0.195 | 0.124 | 0.195 | Spasmolytic | 0.195 0.124 DBMET03416 | ||
| 0.106 | 0.036 | 0.106 | Dopamine antagonist | 0.106 0.036 DBMET03416 | ||
| 0.101 | 0.034 | 0.101 | Opioid kappa receptor antagonist | 0.101 0.034 DBMET03416 | ||
| 0.134 | 0.068 | 0.134 | Tubulin antagonist | 0.134 0.068 DBMET03416 | ||
| 0.093 | 0.035 | 0.093 | Dopamine D2 antagonist | 0.093 0.035 DBMET03416 | ||
| 0.153 | 0.099 | 0.153 | Catenin beta inhibitor | 0.153 0.099 DBMET03416 | ||
| 0.131 | 0.079 | 0.131 | Neurotrophic factor | 0.131 0.079 DBMET03416 | ||
| 0.093 | 0.044 | 0.093 | Hematopoietic | 0.093 0.044 DBMET03416 | ||
| 0.051 | 0.007 | 0.051 | Somatostatin 3 antagonist | 0.051 0.007 DBMET03416 | ||
| 0.068 | 0.026 | 0.068 | Prolactin release inhibitor | 0.068 0.026 DBMET03416 | ||
| 0.076 | 0.035 | 0.076 | Dopamine D1 antagonist | 0.076 0.035 DBMET03416 | ||
| 0.059 | 0.02 | 0.059 | Farnesyltransferase inhibitor | 0.059 0.02 DBMET03416 | ||
| 0.08 | 0.048 | 0.08 | Alpha 2a adrenoreceptor antagonist | 0.08 0.048 DBMET03416 | ||
| 0.128 | 0.098 | 0.128 | Cholinergic | 0.128 0.098 DBMET03416 | ||
| 0.147 | 0.117 | 0.147 | Clk dual-specificity kinase inhibitor | 0.147 0.117 DBMET03416 | ||
| 0.052 | 0.029 | 0.052 | AMPA receptor antagonist | 0.052 0.029 DBMET03416 | ||
| 0.055 | 0.035 | 0.055 | Acetylcholine M2 receptor agonist | 0.055 0.035 DBMET03416 | ||
| 0.039 | 0.021 | 0.039 | p53 inhibitor | 0.039 0.021 DBMET03416 | ||
| 0.066 | 0.05 | 0.066 | Glutamate (mGluR7) antagonist | 0.066 0.05 DBMET03416 | ||
| 0.079 | 0.063 | 0.079 | MAP-kinase-activated kinase inhibitor | 0.079 0.063 DBMET03416 | ||
| 0.032 | 0.016 | 0.032 | Endothelin receptor antagonist | 0.032 0.016 DBMET03416 | ||
| 0.121 | 0.106 | 0.121 | Dual specificity tyrosine-phosphorylation regulated kinase 1B inhibitor | 0.121 0.106 DBMET03416 | ||
| 0.06 | 0.046 | 0.06 | 5 Hydroxytryptamine 5A antagonist | 0.06 0.046 DBMET03416 | ||
| 0.049 | 0.037 | 0.049 | Factor III inhibitor | 0.049 0.037 DBMET03416 | ||
| 0.049 | 0.038 | 0.049 | 5 Hydroxytryptamine 1 agonist | 0.049 0.038 DBMET03416 | ||
| 0.07 | 0.058 | 0.07 | MAP-kinase-activated kinase 2 inhibitor | 0.07 0.058 DBMET03416 | ||
| 0.048 | 0.037 | 0.048 | Bromodomain-containing protein 3 inhibitor | 0.048 0.037 DBMET03416 | ||
| 0.086 | 0.075 | 0.086 | Butyrylcholinesterase inhibitor | 0.086 0.075 DBMET03416 | ||
| 0.148 | 0.138 | 0.148 | Potassium channel (Voltage-sensitive) blocker | 0.148 0.138 DBMET03416 | ||
| 0.021 | 0.012 | 0.021 | Endothelin B receptor antagonist | 0.021 0.012 DBMET03416 | ||
| 0.098 | 0.091 | 0.098 | Activin receptor-like kinase 4 inhibitor | 0.098 0.091 DBMET03416 | ||
| 0.049 | 0.043 | 0.049 | 5 Hydroxytryptamine 1B agonist | 0.049 0.043 DBMET03416 | ||
| 0.021 | 0.015 | 0.021 | Endothelin A receptor antagonist | 0.021 0.015 DBMET03416 | ||
| 0.012 | 0.007 | 0.012 | Immunosuppressant Cyclosporine-like | 0.012 0.007 DBMET03416 | ||
| 0.06 | 0.055 | 0.06 | Alpha adrenoreceptor agonist | 0.06 0.055 DBMET03416 | ||
| 0.093 | 0.092 | 0.093 | 5 Hydroxytryptamine 2B antagonist | 0.093 0.092 DBMET03416 | ||
| 0.11 | 0.109 | 0.11 | Activin receptor-like kinase 2 inhibitor | 0.11 0.109 DBMET03416 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |